Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target.

Pharmacol Res Perspect · 2016 · PMC4777260 · PMID 26977298

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

3 B, bottom panel), while the C4 dose displayed highly significant protection from thrombosis at a limited cost on bleeding.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.